Supply chain security and transparency is a key part of the risk mitigation strategy of companies manufacturing clinical diagnostic assays.
Prior to the COVID-19 crisis, complex global supply chains carefully balanced capacity with demand, while cost-cutting initiatives pushed towards lower-cost raw material providers located in different geographies.
COVID-19-driven regional manufacturing shutdowns, surge demands, and logistics disruptions have placed significant pressure on clinical diagnostic supply chains, resulting in raw material shortages and delays.
Offered Free by: MilliporeSigma
See All Resources from: MilliporeSigma
This download should complete shortly. If the resource doesn't automatically download, please, click here.